UA97468C2 - Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства - Google Patents

Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства

Info

Publication number
UA97468C2
UA97468C2 UAA200800333A UAA200800333A UA97468C2 UA 97468 C2 UA97468 C2 UA 97468C2 UA A200800333 A UAA200800333 A UA A200800333A UA A200800333 A UAA200800333 A UA A200800333A UA 97468 C2 UA97468 C2 UA 97468C2
Authority
UA
Ukraine
Prior art keywords
combination
xanthines
piperidin
medicament
amino
Prior art date
Application number
UAA200800333A
Other languages
English (en)
Ukrainian (uk)
Inventor
Франк Химмельсбах
Эльке Лангкопф
Маттиас Экхардт
Михаель Марк
Роланд Майер
Рихард Херманн Лотц Ральф
Мохаммад Тадайон
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг
Publication of UA97468C2 publication Critical patent/UA97468C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Abstract

В заявке описана комбинация, которая содержит замещенные ксантины общей формулы (I)в которой R-Rимеют указанные в п. 1 формулы изобретения значения, их таутомеры, их стереоизомеры, их смеси или их соли, которые имеют ценные фармакологические свойства, прежде всего ингибирующее действие на активность дипептидилпептидазы-IV ( DPP-IV).
UAA200800333A 2002-08-21 2003-08-18 Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства UA97468C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10238243A DE10238243A1 (de) 2002-08-21 2002-08-21 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UA97468C2 true UA97468C2 (ru) 2012-02-27

Family

ID=31197174

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200800333A UA97468C2 (ru) 2002-08-21 2003-08-18 Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства

Country Status (4)

Country Link
CN (2) CN101503409B (ru)
DE (1) DE10238243A1 (ru)
UA (1) UA97468C2 (ru)
ZA (1) ZA200500087B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
CA2790643A1 (en) * 2010-02-19 2011-08-25 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
BR112012025592A2 (pt) 2010-04-06 2019-09-24 Arena Pharm Inc moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102617566B (zh) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 吡啶并咪唑烷衍生物
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN104478879B (zh) * 2014-12-26 2016-03-02 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物
CN104478880B (zh) * 2014-12-26 2016-03-02 浙江永太科技股份有限公司 作为dpp-iv抑制剂的双胍衍生物
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
ZA200500087B (en) 2006-07-26
CN101503409A (zh) 2009-08-12
CN101503409B (zh) 2014-01-22
DE10238243A1 (de) 2004-03-04
CN101503408A (zh) 2009-08-12
CN101503408B (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
UA97468C2 (ru) Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства
UA84275C2 (ru) 8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение как лекарственных средств
MY144322A (en) 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
ATE323093T1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
TWI265163B (en) Novel pyrido[2,1-a]isoquinoline derivatives
TW200512210A (en) Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
RS20050939A (en) Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors
MXPA03010810A (es) Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
AU2003258621A1 (en) Novel purine derivatives, production and use thereof as medicaments
UA74346C2 (ru) Производные аминодикарбоновых кислот, их применение и лекарственное средство
PL312225A1 (en) Novel chemical compounds exhibiting pde iv inhibiting activity
YU65803A (sh) Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
AU7775401A (en) Proline derivatives and use thereof as drugs
MXPA04003759A (es) Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv.
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
UA87835C2 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use in the form of a dpp inhibitor
RS20060294A (en) Thiozolidinones, production and use thereof as medicaments
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
WO2004004725A3 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
YU20902A (sh) Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima
NZ518545A (en) Aromatic di-keto derivatives, processes for their production and their use as a pharmaceutical